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Abstract
IMPORTANCE Infection with SARS-CoV-2 is associated with fatigue and sleep problems long after
the acute phase of COVID-19. In addition, there are concerns of SARS-CoV-2 infection causing
psychiatric illness; however, evidence of a direct effect is inconclusive.
OBJECTIVE To assess risk of risk of incident or repeat psychiatric illness, fatigue, or sleep problems
following SARS-CoV-2 infection and to analyze changes according to demographic subgroups.
DESIGN, SETTING, AND PARTICIPANTS This cohort study assembled matched cohorts using the
Clinical Practice Research Datalink Aurum, a UK primary care registry of 11 923 499 individuals aged
16 years or older. Patients were followed-up for up to 10 months, from February 1 to December 9,
2020. Individuals with less than 2 years of historical data or less than 1 week follow-up were
excluded. Individuals with positive results on a SARS-CoV-2 test without prior mental illness or with
anxiety or depression, psychosis, fatigue, or sleep problems were matched with up to 4 controls
based on sex, general practice, and year of birth. Controls were individuals who had negative SARS-
CoV-2 test results. Data were analyzed from January to July 2021.
EXPOSURE SARS-CoV-2 infection, determined via polymerase chain reaction testing.
MAIN OUTCOMES AND MEASURES Cox proportional hazard models estimated the association
between a positive SARS-CoV-2 test result and subsequent psychiatric morbidity (depression,
anxiety, psychosis, or self-harm), sleep problems, fatigue, or psychotropic prescribing. Models
adjusted for comorbidities, ethnicity, smoking, and body mass index.
RESULTS Of 11 923 105 eligible individuals (6 011 020 [50.4%] women and 5 912 085 [49.6%] men;
median [IQR] age, 44 [30-61] years), 232 780 individuals (2.0%) had positive result on a SARS-
CoV-2 test. After applying selection criteria, 86 922 individuals were in the matched cohort without
prior mental illness, 19 020 individuals had prior anxiety or depression, 1036 individuals had
psychosis, 4152 individuals had fatigue, and 4539 individuals had sleep problems. After adjusting for
observed confounders, there was an association between positive SARS-CoV-2 test results and
psychiatric morbidity (adjusted hazard ratio [aHR], 1.83; 95% CI, 1.66-2.02), fatigue (aHR, 5.98; 95%
CI, 5.33-6.71), and sleep problems (aHR, 3.16; 95% CI, 2.64-3.78). However, there was a similar risk
of incident psychiatric morbidity for those with a negative SARS-CoV-2 test results (aHR, 1.71; 95% CI,
1.65-1.77) and a larger increase associated with influenza (aHR, 2.98; 95% CI, 1.55-5.75).
CONCLUSIONS AND RELEVANCE In this cohort study of individuals registered at an English
primary care practice during the pandemic, there was consistent evidence that SARS-CoV-2 infection
(continued)
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Abstract (continued)
was associated with increased risk of fatigue and sleep problems. However, the results from the
negative control analysis suggest that unobserved confounding may be responsible for at least some
of the positive association between COVID-19 and psychiatric morbidity.
JAMA Network Open. 2021;4(11):e2134803. doi:10.1001/jamanetworkopen.2021.34803
Introduction
Many people infected with SARS-CoV-2 experience symptoms beyond the acute phase of COVID-19,
particularly fatigue, brain fog, and sleep problems.1,2 Studies have also reported worsening mental
health and an increased risk of psychiatric illness after COVID-19,3-8 and mechanisms linking the
immune system, inflammation, and the brain have been proposed.9,10 Notably, not all studies have
found an association of COVID-19 with anxiety or depression.11
To date, 37% of the US population has been infected with SARS-CoV-2 and only approximately
1 in 4 individuals present for testing.12,13 Observational studies investigating the outcomes associated
with SARS-CoV-2 infection may be confounded by several sources affecting the likelihood that
somebody is infected (eg, their occupation), the likelihood they present to services (eg,
comorbidities), or the likelihood they seek a test (eg, health anxiety). When unobserved confounding
is suspected, the extent that confounding bias is evident can be examined using a negative control.14
In a negative exposure control, a variable with no conceivable direct effect on the outcome, but with
a similar confounding structure, is substituted for the exposure under investigation. If the result from
the negative control is similar to that observed using the primary exposure, then unobserved
confounding is implicated.
We examined the association between SARS-CoV-2 infection and psychiatric morbidity (ie,
anxiety, depression, self-harm, psychosis, and prescription of psychotropic medication), sleep
problems, and fatigue using UK primary care data. In the United Kingdom, most of health care takes
place in primary care. Therefore, reexamining associations within this population might provide
further detail as to the outcomes associated with COVID-19 in the population. To our knowledge, this
is the first study to use a negative test result as a negative exposure control to detect unobserved
confounding.
We consider both incident events as well as outcomes in people with preexisting mental illness,
fatigue, or sleep problems. Our primary hypothesis was that SARS-CoV-2 infection would be
associated with increased likelihood of new or repeat presentation of psychiatric morbidity, sleep
problems, or fatigue independently of confounders. We also hypothesized that the increase in risk
would be greatest for women and those living in more socioeconomically deprived areas. We
investigated the specificity of infection with SARS-CoV-2 and psychological outcomes by repeating
our analysis in individuals with an influenza diagnosis.
Methods
For this cohort study, data access was granted following approval from the Independent Scientific
Advisory Committee for Medicines and Healthcare Products Regulatory Agency Database
Research.15 All patient data were deidentified; thus, the requirement for patient consent was waived
by CRPD. Individual patients can opt out of sharing their records with the Clinical Practice Research
Datalink (CPRD) Aurum. This study is prepared in line with the Reporting of Studies Conducted Using
Observational Routinely-Collected Data (RECORD) statement. The protocol was preregistered
before any outcomes were analyzed and is available elsewhere.16
JAMA Network Open | Psychiatry SARS-CoV-2 and Subsequent Psychological Distress, Psychotropic Prescribing, Fatigue, and Sleep Problems
JAMA Network Open. 2021;4(11):e2134803. doi:10.1001/jamanetworkopen.2021.34803 (Reprinted) November 16, 2021 2/14
Downloaded From: https://jamanetwork.com/ on 11/18/2021
Data Source
Cohorts were assembled from the CPRD Aurum data set, a large UK primary care registry covering 19
million patients.17 It contains information on clinical events recorded by health care professionals,
including diagnosis, symptoms, and therapies.
Eligible Cohort
Eligible individuals were those aged 16 years or older during 2020 and registered at a CPRD Aurum
participating clinical practice from February 1 to December 8, 2020. Eligible follow-up began on the
latest date of February 1, 2020, or their clinical practice registration, and ended at the earliest date
of their death, the date they transferred out of a clinical practice, or the end of data collection
(December 9, 2020). A total of 394 individuals were excluded if they had an indeterminate sex
recorded. This resulted in 11 923 105 individuals for matching.
Exposure
Exposure to SARS-CoV-2 was defined as a positive result on a polymerase chain reaction (PCR) test
using codes developed by the UK Medicines and Healthcare Products Regulatory Agency.18 In the
United Kingdom, while most testing took place in the community, in primary care, individuals
presenting with symptoms consistent with COVID-19 underwent PCR testing. In addition, since July
20, 2020, primary care physicians were notified of all PCR test results, regardless of outcome.19 In
total, 232 780 of 11 923 105 eligible individuals (2.0%) had a record of a positive SARS-CoV-2 test
result during the observation period.
Outcome
The primary outcomes were a diagnosis with or symptoms relating to depression, anxiety disorders,
self-harm, affective or nonaffective psychosis, sleep problems, and fatigue or fatigue-like syndromes
(eg, postviral fatigue syndrome). There were few cases of posttraumatic stress disorder (PTSD) so,
in a departure from our protocol, these were combined with anxiety disorders. Secondary outcomes
were prescriptions for psychotic medications (ie, antidepressants, anxiolytics, antipsychotics, mood
stabilizers, benzodiazepines, and nonbenzodiazepines hypnotics). Outcome codes were identified in
a prior analysis and are published elsewhere.20 Two senior clinical academics (C.A.C.-G. and N.K.)
reviewed the clinical code list, and a senior academic pharmacist (D.M.A.) reviewed the medication
code list.
Covariates
Covariates were identified from 10 years of patient data recorded before the start of each individual’s
follow-up. Comorbidities were identified using individual diseases used for the Charlson comorbidity
index21: cancer, cerebrovascular disease, chronic pulmonary disease, congestive heart failure,
connective tissue disease, dementia, diabetes, HIV/AIDS, hemiplegia, myocardial infarction, liver
disease, renal disease, peripheral vascular disease, posterior vitreous detachment, and peptic ulcer
disease. Additional data were extracted on sex, year of birth, and the practice’s Index of Multiple
Deprivation score, an area-level ranking of socioeconomic deprivation divided into quintiles
according to the national distribution. In the UK general practices, ethnicity is self-reported during
registration or at clinical consultations. There are 296 different ethnicity codes in the CPRD, and
these were categorized by the analysis team (M.P. and M.C.) as White, Asian, Black, Mixed and other
(eg, Arab, Cook Island Māori, and Latin American) (eTable 1 in the Supplement).
Matched Cohorts
Five cohorts were constructed by matching individuals with a positive SARS-CoV-2 test result during
follow-up with unexposed individuals (eFigure 1 in the Supplement). An individual’s earliest date of
positive test result was defined as the index date. The first cohort (hereafter incident cohort)
excluded individuals with recorded histories of psychiatric morbidity, fatigue, sleep problems, or
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psychotropic medications in the 5 years prior to their index date. The remaining 4 prevalent cohorts
comprised individuals with common mental illness, psychosis, sleep problems, or fatigue in the last
6 months. Individuals in the common mental illness and psychosis cohorts must also have had a
prescription for antidepressants, anxiolytics or antipsychotics, or mood stabilizers in the last 6
months. Individuals were not excluded from a prevalent cohort based on having a history of another
mental illness, fatigue, or sleep problem. The prevalent cohorts were not mutually exclusive but were
mutually exclusive with the incident cohort.
We excluded individuals with less than 1 week of eligible follow-up from their index date or less
than 2 years registration prior to their index date to ensure adequate capture for prior mental
illnesses. Patients were ineligible for being in the unexposed group if they had a record indicating
suspected or confirmed COVID-19 in their history or in the week following the index date. Unexposed
individuals may have had a positive test result at a later time, thus unexposed individuals could enter
the cohort as an exposed individual at a later time. After these criteria were applied, up to 4
unexposed individuals were selected for each exposed individual, regardless of whether or not they
had been selected previously (ie, matching with replacement), matched on sex, clinical practice, and
year of birth. The psychosis cohort (in which there were fewer available unexposed individuals) was
matched solely on sex and practice.
Additional Cohorts
Two further cohorts were constructed. The first substituted individuals with negative SARS-CoV-2
test results for those with a positive test result (560 495 negative test cases matched with 2 232 733
comparators) and proceeded with the same analysis. The second repeated the analysis using those
recorded by their general practitioner as having influenza or influenza-like symptoms and with a
negative SARS-CoV-2 test result within 2 weeks. For the negative test cohort, we expected that there
would be little (or no) association between receiving a negative test result (vs comparators) and any
of the outcomes considered. Any divergence from a null finding would indicate potential bias from
unobserved confounders. For the influenza cohort, we expected to see an increase in fatigue,22 but
to a lesser extent than that seen for individuals with SARS-CoV-2 infection.3
Statistical Analysis
The index date for the exposed individuals became the start of follow-up for all in a matched set.
Censoring occurred at death, when the practice ceased collecting data, or when the individual
transferred to another practice. Hazard ratios (HRs) were estimated using Cox proportional hazard
models, stratified on each matched set and with weights representing the number of times an
individual was in a cohort. The proportional hazard assumption was investigated by graphically
examining the cumulative hazard function and the scaled Schoenfeld residuals (eFigure 2 in the
Supplement).
Adjusted models included variables for ethnicity, comorbidities (as binary indicators), smoking
status, body mass index (BMI, calculated as weight in kilograms divided by height in meters squared;
linear and squared term) and a variable indicating how long the individual had been at a clinical
practice. Effect modification was explored by including a multiplicative interaction between the
exposure and (individually) the covariates: age (categorized as 16-24, 25-34, 35-49, 50-59, 60-69,
70-79, and 80 years), sex, Index of Multiple Deprivation quintile of the general practice, and
follow-up time elapsed since index date (<1 month, 1 to <3 months, 3 to <6 months, or 6-10 months).
The model using follow-up time was used to loosen the assumption of nonproportional hazards over
the whole of follow-up.
There were missing data for ethnicity (2 327 219 individuals [19.5%]), smoking (881 268
individuals [7.4%]), and BMI (1 757 001 individuals [14.7%]). To retain individuals, 10 imputed data
sets were estimated after matching, using chained equations. Multiple imputation models included
all covariates, a variable indicating the size of the general practice, and the patient’s height or weight
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(if recorded). Adjusted Cox models were fitted to each imputed data set, and estimates were
combined using Rubin rules.
We conducted 3 preplanned sensitivity analyses. For the first, we investigated the introduction
of widespread testing by fitting an interaction between period (before vs after September 1, 2020)
and the exposure. For the second sensitivity analysis, a propensity score was calculated and used as a
covariate in the Cox model. For calculation of the propensity score, missing data items were given
separate categories, and interactions between variables were included. The third sensitivity analysis
repeated the analysis of the incident cohort but including only diagnosis codes in the outcome
definition.
A post hoc sensitivity analysis was conducted after review to test robustness of findings to
whether exposed and unexposed individuals were engaged with health care services. Thus, the
incident matched cohort was constructed, again restricting to those who had routine clinical data (ie,
BMI, ethnicity, or smoking status) recorded in the last 2 years, 1 year, and 6 months.
Stata statistical software version 16 (StataCorp) was used for all analyses and graphs were
produced using R statistical software version 4.0.3 (R Project for Statistical Computing). P values
were 2-sided, but we did not use a binary threshold to denote significance. Data were analyzed from
January to July 2021.
Results
Of 11 923 105 individuals (6 011 020 [50.4%] women and 5 912 085 [49.6%] men; median [IQR] age,
44 [30-61] years) in the eligible cohort, 232 780 (2.0%) were recorded as having a positive PCR test
result for SARS-CoV-2 during their follow-up. Most positive test results occurred between April and
May 2020 and October and November 2020 (eFigure 3 in the Supplement). Individuals with a
positive test result were more likely than those without to be women (130 775 [56.2%] women vs
5 880 245 [50.3%]) (Table 1), in the youngest or oldest age groups (45 456 individuals [19.5%] vs
1 665 762 [14.3%] aged 16-24 years; 16 083 individuals (6.9%) vs 683 993 individuals (5.9%) aged
80 years), and have higher BMI (median [IQR], 26.4 [22.9-30.8] vs 25.8 [22.6-29.7]) and more
recorded comorbidities (51 500 individuals [22.1%] vs 2 303 458 individuals [19.7%] with 1
comorbid conditions). Individuals with positive SARS-CoV-2 test results were also more likely to have
a clinical record in the preceding 5 years signifying psychiatric morbidity, fatigue, sleep problems, or
a psychotropic medication prescription (Table 1).
Outcomes in Individuals Without Prior Mental Illness, Fatigue, or Sleep Problems
(Incident Cohort)
The median (IQR) follow-up of the incident cohort was 6.3 (4.0-9.3) weeks. After matching on age,
sex, and registered practice, and adjusting for ethnicity, smoking status, BMI, and comorbidities,
having a positive result on a SARS-CoV-2 test was associated with an increase in risk of any psychiatric
morbidity (adjusted HR [aHR], 1.83; 95% CI, 1.66-2.02) and of being prescribed psychotropic
medication (aHR, 2.24; 95% CI, 2.09-2.40) (Table 2). The absolute risks were low: an estimated 1.4%
of patients with a positive SARS-CoV-2 test result presented with psychiatric morbidity at 6 months,
compared with 0.9% of individuals with a negative test result (eTable 2 in the Supplement).
For almost all outcomes considered, positive SARS-CoV-2 test results were associated with
increased risk. The largest increases were for receipt of antipsychotics (aHR, 7.61; 95% CI,
5.00-11.60), fatigue (aHR, 5.98; 95% CI, 5.33-6.71), receipt of nonbenzodiazepine hypnotics (aHR,
4.90; 95% CI, 4.00-5.99), receipt of mood stabilizers (a HR, 3.55; 95% CI, 2.74-4.61), and sleep
problems (aHR, 3.16; 95% CI, 2.64-3.78).
There was effect modification by age, such that the association between SARS-CoV-2 infection
and psychiatric morbidity was greater for older age groups (eg, 80 years: aHR, 4.17; 95% CI, 2.67-
6.53 vs 16-24 years: aHR, 1.28; 95% CI, 1.06-1.55). For fatigue and sleep disorder, the association was
greatest for those aged 60 to 69 years and remained elevated for all groups (Table 3). For all
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outcomes, women with positive SARS-CoV-2 test results had a higher incidence than men; however,
the relative increase associated with a positive test result was larger for men. There was no
association of effect modification by deprivation quintile. For sleep or psychiatric morbidity, the
association was similar over follow-up.
Table 1. Characteristics of Available Unmatched Cohort According to SARS-CoV-2 Test Results
Characteristic
Positive SARS-CoV-2 test results, No. (%)
Yes (n = 232 780) No (n = 11 690 325)
Sex
Women 130 775 (56.2) 5 880 245 (50.3)
Men 102 005 (43.8) 5 810 080 (49.7)
Age group, y
16-24 45 456 (19.5) 1 665 762 (14.3)
25-34 41 336 (17.8) 2 208 954 (18.9)
35-49 56 983 (24.5) 2 881 606 (24.7)
50-59 39 119 (16.8) 1 827 489 (15.6)
60-69 21 359 (9.2) 1 362 308 (11.7)
70-79 12 444 (5.4) 1 060 213 (9.1)
≥80 16 083 (6.9) 683 993 (5.9)
Race and ethnicitya
White 152 885 (79.5) 7 545 915 (80.3)
Asian 25 988 (13.5) 996 746 (10.6)
Black 7540 (3.9) 499 926 (5.3)
Mixed 3325 (1.7) 185 221 (2.0)
Other 2646 (1.4) 175 694 (1.9)
Missing 40 396b 2 286 823b
BMI category
<18.5 7964 (3.9) 386 194 (3.9)
≥18.5 to <25 73 790 (36.1) 3 975 991 (39.9)
≥25 to <30 64 222 (31.4) 3 217 104 (32.3)
≥30 to <40 49 321 (24.1) 2 058 755 (20.7)
≥40 9106 (4.5) 323 657 (3.3)
Missing 28 377b 1 728 624b
Time at clinical practice, median (IQR), y 9.6 (2.3-21.0) 9.4 (2.7-21.4)
Comorbidities, No.c
0 181 280 (77.9) 9 386 867 (80.3)
1 26 143 (11.2) 1 332 044 (11.4)
2-4 23 262 (10.0) 922 004 (7.9)
≥5 2095 (0.9) 49 410 (0.4)
Psychiatric morbidity in the last 5 y
Depression 38 727 (16.6) 1 601 431 (13.7)
Anxiety 31 072 (13.4) 1 271 468 (10.9)
Psychosis 2941 (1.3) 136 001 (1.2)
Eating disorder 1344 (0.6) 47 018 (0.4)
Personality disorder 726 (0.3) 42 531 (0.4)
Self-harm 2975 (1.3) 137 826 (1.2)
Fatigue 18 396 (7.9) 665 652 (5.7)
Sleep disorder 16 759 (7.2) 669 528 (5.7)
Medication in the last 5 y
Antidepressants 65 364 (28.1) 2 681 383 (22.9)
Benzodiazepines 20 571 (8.8) 826 794 (7.1)
Nonbenzodiazepine hypnotics 12 596 (5.4) 542 565 (4.6)
Antipsychotics 5228 (2.3) 209 463 (1.8)
Mood stabilizers 15 306 (6.6) 586 523 (5.0)
a Race and ethnicity categorized from 296 clinical
codes. Other race or ethnicity includes Arab, Cook
Island Māori, and Latin American. A full list is
provided in eTable 1 in the Supplement.
b Missing data excluded from percentages.
c List of comorbidities from the Charlson
comorbidity index.
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Outcomes in Individuals With Prior History of Common Mental Illness, Psychosis,
Fatigue, and Sleep Problems
For those with preexisting common mental illness (ie, depression or anxiety disorders), there was no
association of a positive SARS-CoV-2 test result with increased risk of subsequent depression or
anxiety events (Figure 1; eTable 3 in the Supplement). However, there was an increase in the risk of
new prescriptions for antidepressants (aHR, 1.20; 95% CI, 1.13-1.26) and a larger increase for new
prescriptions for benzodiazepines (aHR, 1.91; 95% CI, 1.68-2.17), and a positive SARS-CoV-2 test
result was associated with more than 2-fold higher risk of subsequent fatigue (aHR, 2.24; 95% CI,
1.99-2.53).
There was no evidence of an increased risk of depression or anxiety associated with SARS-CoV-2
infection for those with preexisting psychosis or fatigue. There was an increased risk of depression
and anxiety disorders associated with having a positive SARS-CoV-2 test result for those with
preexisting sleep problems (depression: aHR, 1.35; 95% CI, 1.09-1.67; anxiety disorders: aHR, 1.42;
95% CI, 1.09-1.86) and an increased risk of subsequent fatigue associated with having a positive
SARS-CoV-2 test result for all matched cohorts.
Negative Test Results and Influenza Cohorts
Among individuals with a negative SARS-CoV-2 test result, there was an increased risk of psychiatric
morbidity compared with matched controls in the general population (Figure 2). There was a similar
association to the main analysis between having a negative test result and the risk of all
subcategories of psychiatric morbidity, fatigue, and sleep problems (eTable 4 in the Supplement).
There was an association between having an influenza-like illness and either incident psychiatric
Table 2. Comparison of Incident Outcomes Between Patients With a Positive SARS-CoV-2 Test Result








SARS-CoV-2 447 30.24 1.80 (1.63-1.98) 1.83 (1.66-2.02)
Unexposed 1045 17.39 1 [Reference] 1 [Reference]
Depression SARS-CoV-2 230 15.52 1.71 (1.50-1.95) 1.74 (1.51-2.00)
Unexposed 571 9.49 1 [Reference] 1 [Reference]
Anxiety SARS-CoV-2 298 20.12 1.85 (1.65-2.08) 1.93 (1.71-2.18)
Unexposed 671 11.15 1 [Reference] 1 [Reference]
Psychosis SARS-CoV-2 21 1.41 2.34 (1.48-3.70) 1.84 (0.93-3.64)
Unexposed 36 0.60 1 [Reference] 1 [Reference]
Self-harm SARS-CoV-2 13 0.87 2.09 (1.20-3.64) 2.21 (1.11-4.39)
Unexposed 25 0.41 1 [Reference] 1 [Reference]
Sleep disorders SARS-CoV-2 190 12.82 3.31 (2.82-3.89) 3.16 (2.64-3.78)
Unexposed 236 3.92 1 [Reference] 1 [Reference]
Fatigue SARS-CoV-2 579 39.29 6.10 (5.47-6.80) 5.98 (5.33-6.71)
Unexposed 414 6.88 1 [Reference] 1 [Reference]
Any psychotropic
medication
SARS-CoV-2 1055 72.05 2.41 (2.26-2.57) 2.24 (2.09-2.40)
Unexposed 1848 30.82 1 [Reference] 1 [Reference]
Antidepressants SARS-CoV-2 583 39.54 1.79 (1.65-1.95) 1.72 (1.57-1.88)
Unexposed 1358 22.62 1 [Reference] 1 [Reference]
Benzodiazepines SARS-CoV-2 266 17.95 3.84 (3.33-4.42) 3.50 (2.95-4.15)
Unexposed 305 5.07 1 [Reference] 1 [Reference]
Nonbenzodiazepine
hypnotics
SARS-CoV-2 173 11.67 4.95 (4.10-5.97) 4.90 (4.00-5.99)
Unexposed 148 2.46 1 [Reference] 1 [Reference]
Antipsychotics SARS-CoV-2 83 5.59 6.73 (4.99-9.08) 7.61 (5.00-11.60)
Unexposed 63 1.05 1 [Reference] 1 [Reference]
Mood stabilizers SARS-CoV-2 105 7.08 3.80 (3.04-4.75) 3.55 (2.74-4.61)
Unexposed 115 1.91 1 [Reference] 1 [Reference]
a Adjusted for race and ethnicity, smoking, body mass
index, and comorbidities and after multiple
imputation.
JAMA Network Open | Psychiatry SARS-CoV-2 and Subsequent Psychological Distress, Psychotropic Prescribing, Fatigue, and Sleep Problems
JAMA Network Open. 2021;4(11):e2134803. doi:10.1001/jamanetworkopen.2021.34803 (Reprinted) November 16, 2021 7/14

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































JAMA Network Open | Psychiatry SARS-CoV-2 and Subsequent Psychological Distress, Psychotropic Prescribing, Fatigue, and Sleep Problems
JAMA Network Open. 2021;4(11):e2134803. doi:10.1001/jamanetworkopen.2021.34803 (Reprinted) November 16, 2021 8/14
Downloaded From: https://jamanetwork.com/ on 11/18/2021
morbidity, sleep, fatigue, or psychotropic prescribing. Prior to matching, individuals with a negative
SARS-CoV-2 test result and those with influenza over follow-up had a higher rate of prior mental
illness than those in the group with positive SARS-CoV-2 test results (eTable 5 in the Supplement).
Sensitivity Analyses
There were some significant interactions between period of testing and the positive test result. For
individuals who had positive test results prior to September 1, 2020, there was a stronger association
between having a positive SARS-CoV-2 test result and psychiatric morbidity or psychotropic
medication than those who had positive results on or after September 1, 2020 (eTable 6 in the
Supplement). The estimates, after adjusting for a propensity score, were of a similar magnitude to
that seen in the main analysis (eTable 7 in the Supplement). The estimates for anxiety and depression
were also similar after including only diagnostic codes in the outcome; however, for psychosis, there
was little evidence of an increase associated with SARS-CoV-2 infection (eTable 8 in the Supplement).
When the cohort was restricted to those with recent clinical contact, there were similar associations
to those seen in the main analysis (eTable 9 in the Supplement).











































































Risk of psychotropic medicationsB
CMD indicates common mental disorders. Estimates are provided in eTable 3 in the Supplement.
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Discussion
In this cohort study, we found that SARS-CoV-2 infection confirmed with a positive PCR test result
was associated with increased risk of incident psychiatric morbidity, sleep problems, and fatigue in
the following months. However, sensitivity analyses provided doubt about whether some of these
outcomes were directly associated with SARS-CoV-2 infection. Notably, using the same processes as
the analysis of patients with a positive SARS-CoV-2 test result (eg, selection criteria, confounding
control), individuals with a negative SARS-CoV-2 test result also experienced a substantial increase in
risk of incident psychiatric morbidity. This association was of similar magnitude and with overlapping
CIs to that observed in people with a positive SARS-CoV-2 test results. Having a negative test result
for SARS-CoV-2, in and of itself, is unlikely to cause psychiatric morbidity through any direct
mechanism; rather, this indicates there are unobserved confounders linking the likelihood of
undergoing a test and the likelihood of having an incident psychiatric episode during the COVID-19
pandemic.
We believe the most likely unobserved confounding variables are occupation and health
anxiety. While many individuals were placed on furlough or worked from home, many sectors of work
(eg, health care workers) were required to continue as usual, raising the likelihood of exposure to
SARS-CoV-2 and potentially leading to excess psychological strain.23 In addition, those who seek a
test for COVID-19 symptoms could already be experiencing health anxieties that might indicate
future mental illness. Those with a negative test result had a higher proportion of prior mental illness
than those with a positive test, perhaps indicating that health anxiety might be more strongly
associated with having a negative test result rather than a positive one. It has been estimated that
approximately three-fourths of individuals infected with SARS-CoV-2 have not been tested,13 and the
likelihood of seeking a test may be guided by similar behavioral factors regardless of whether the
results would be positive or negative. The negative exposure control analysis showed these factors
should not be ignored, and while this does not rule out a direct association of SARS-CoV-2 infection
with subsequent psychiatric morbidity, it provides substantial doubt.
We included a separate investigation of individuals exposed to influenza during the same
periods to examine the specificity of the association of incident psychiatric morbidity, fatigue, and
sleep problems with SARS-CoV-2 infection as opposed to other respiratory diseases. For all
outcomes, the increase in risk was considerably larger for individuals presenting for primary care with
influenza than with SARS-CoV-2 infection. This is likely because these form a particularly selective
Figure 2. Adjusted Hazard Ratios From Incident COVID-19, Negative Exposure, and Influenza Cohorts

























Psychotropic medications that were prescribed 6
months prior to index date were excluded. Estimates
are provided in eTable 4 in the Supplement.
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group: overall there were fewer cases of influenza observed during the COVID-19 pandemic,24 and
individuals who present with influenza may have been more likely to have severe infection,
preexisting morbidity, and/or psychological risk factors.
Our finding contrasts with 2 recent studies using US administrative data3,4 that reported that
individuals with positive test results for SARS-CoV-2 had approximately 2-fold higher risk of
subsequent psychiatric illness compared with those with influenza infection. There are some key
design differences that may explain this: the US analysis did not follow-up individuals with SARS-
CoV-2 infection and the controls from the same date, nor did they adjust for geographical area.
Because the pandemic has ecological effects on localized health care systems, as well as on
population mental health, this could introduce substantive biases.25 Also, the US may have
confounding that is less evident in the United Kingdom. For example, in the US, areas with high levels
of socioeconomic deprivation and inequality had significantly higher incidence of COVID-19,26,27
these areas are also likely to have higher rates of mental illness.28,29
Our analysis is in agreement with a Danish registry study that did not find an association
between having positive SARS-CoV-2 test results, vs negative test results, and subsequent mental
illness.11 This analysis excluded patients hospitalized for COVID-19 (which we were unable to do);
however, we note that the US study3 reported similar estimates for those who were hospitalized and
those not.
Limitations
There are several limitations to our study, besides unobserved confounding. First, approximately
8.7% of the population of England had positive results in antibody testing for SARS-CoV-2 by
December 2020,30 indicating they had previously been infected, compared with 2.0% of individuals
in the study population who had positive results in SARS-CoV-2 PCR testing. Therefore, the
comparison group will have contained many who had a SARS-CoV-2 infection but were
asymptomatic or were symptomatic and did not report it. This misclassification will likely bias results
toward the null. Second, because testing was relatively scarce during the early phases of the
pandemic and there was no requirement automatically to notify general practices until July 20,
2020, most patients with SARS-CoV-2 infection were identified during the United Kingdom’s second
wave of infections (ie, November-December 2020); therefore, the median follow-up was relatively
short (6.3 weeks). Additionally, the cohort is based on administrative records, rather than active
follow-up, and therefore will have contained some people who moved away. However, the results
were sensitive to participants having recent clinical contact.
Conclusions
This cohort study of individuals with a positive SARS-CoV-2 PCR test result found an association of
SARS-CoV-2 infection with fatigue and sleep problems; however there is some doubt about a direct
association of SARS-CoV-2 with psychiatric outcomes. Other designs may be more appropriate to
investigate the association of SARS-CoV-2 infection with mental health outcomes. For example,
individuals, randomly selected, who took part in serological surveys might be more representative of
the general population and, thus, less susceptible to bias.
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